Rexon-Eye Therapy

Rexon-Eye is an emerging treatment for dry eye disease that uses low-frequency electrical fields to stimulate the tissues around the eyes. This non-invasive therapy aims to improve meibomian gland function and tear film quality.

Understanding the Treatment

Rexon-Eye therapy applies Quantum Molecular Resonance (QMR) technology-a form of low-frequency electrical stimulation-to the periocular area. The treatment is designed to:

• Stimulate cellular activity in the meibomian glands

• Improve the quality and flow of meibum (the oil component of tears)

• Enhance tear film stability

• Provide relief from dry eye symptoms

The therapy is delivered through applicators placed on and around the closed eyelids, with treatment sessions typically lasting 20-30 minutes.

The Treatment Experience

A typical Rexon-Eye treatment course involves:

• 4 sessions performed over approximately 2-3 weeks

• Each session lasts 20-30 minutes

• Treatment is painless-most patients describe a gentle warming sensation

• No anaesthesia is required

• You can return to normal activities immediately

Who May Consider This Treatment

Rexon-Eye therapy is marketed for patients with:

• Evaporative dry eye from meibomian gland dysfunction

• Symptoms not adequately controlled with artificial tears

• Those seeking alternatives to other dry eye treatments

Current Evidence

Important note regarding evidence: Rexon-Eye is a relatively new technology, and the published peer-reviewed research is limited compared to more established treatments. While early studies and clinical observations suggest potential benefit for some patients, large-scale randomised controlled trials are not yet available.

Patients should be aware that:

• The evidence base is still developing

• Individual responses may vary considerably

• Comparison studies with other dry eye treatments are limited

We believe in providing patients with accurate information about the strength of evidence supporting different treatments.

What Results May Be Expected

Based on available data and clinical experience:

• Some patients report improvement in comfort and symptoms

• Effects on tear film parameters have been observed in some studies

• The duration of benefit and need for maintenance treatment are not yet well established

• Not all patients respond to the treatment

Safety Considerations

Rexon-Eye appears to be well-tolerated based on available information:

• Non-invasive with no reported serious adverse effects

• Mild warming sensation during treatment

• No downtime required

As with any newer technology, long-term safety data is limited.

Medical Disclaimer: This information provides general guidance about Rexon-Eye therapy and should not replace professional medical advice. This is an emerging treatment with limited peer-reviewed evidence compared to established dry eye therapies. The information provided reflects currently available data, which may evolve as more research is published. Please consult with our eye care professionals to discuss whether this treatment might be appropriate for your situation and to understand the current evidence base.